Table 1.
Characteristics of patients and healthy controls
| Patients n=1100 | Healthy controls n=303 | |
| Demographics | ||
| Age, years (median, IQR) | 54.2 (42.6–64) | 43 (33–55) |
| Female, no (%) | 602 (54.7) | 226 (74.6) |
| Diseases no (%) | ||
| Rheumatoid arthritis | 366 (33) | ‧‧ |
| Spondyloarthritis | 177 (16.2) | ‧‧ |
| Psoriatic arthritis | 184 (16.8) | ‧‧ |
| Ulcerative colitis | 156 (14.1) | ‧‧ |
| Crohn’s disease | 217 (19.9) | ‧‧ |
| Medication no (%) | ||
| Tumour necrosis factor inhibitor, monotherapy* | 461 (41.9) | ‧‧ |
| Tumour necrosis factor inhibitor combination therapy† | 254 (23.1) | ‧‧ |
| Methotrexate | 220 (20) | ‧‧ |
| Vedolizumab | 46 (4.2) | ‧‧ |
| Janus kinases inhibitor | 33 (3) | ‧‧ |
| Ustekinumab, secukinumab, tocilizumab | 60 (5.5) | ‧‧ |
| Abatacept | 15 (1.4) | ‧‧ |
| Other‡ | 11 (1) | ‧‧ |
| Vaccines no (%) | ||
| BNT162b2 all doses | 596 (54.2) | 163 (53.8) |
| mRNA-1273 all doses | 186 (16.9) | 70 (23.1) |
| Combination of vaccines§ | 318 (28.9) | 70 (23.1) |
Patients received three doses, healthy controls received two doses.
*Tumour necrosis factor inhibitors: infliximab, etanercept, adalimumab, golimumab, certolizumab pegol.
†Combination therapy: Tumour necrosis factor inhibitor in combination with either methotrexate, sulfasalazine, leflunomide or azathioprine.
‡Drugs with less than 10 patients included: sulfasalazine, leflunomide, azathioprine, risankizumab, prednisolone monotherapy.
§Combination of the following vaccines: ChAdOx1, BNT162b2, mRNA-1273.
IQR, Inter quartile range.